190 related articles for article (PubMed ID: 24881568)
21. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
[TBL] [Abstract][Full Text] [Related]
23. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
24. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
25. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
[TBL] [Abstract][Full Text] [Related]
27. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
[TBL] [Abstract][Full Text] [Related]
29. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
[TBL] [Abstract][Full Text] [Related]
30. GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery.
Gupta MK; Vasudevan NT
Curr Top Med Chem; 2019; 19(16):1436-1444. PubMed ID: 31512997
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
[TBL] [Abstract][Full Text] [Related]
32. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
34. The Role and Future of FFA1 as a Therapeutic Target.
Ghislain J; Poitout V
Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
[TBL] [Abstract][Full Text] [Related]
35. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
[TBL] [Abstract][Full Text] [Related]
36. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
38. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
[TBL] [Abstract][Full Text] [Related]
39. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
40. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]